CA2230477A1 - Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels - Google Patents

Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels Download PDF

Info

Publication number
CA2230477A1
CA2230477A1 CA002230477A CA2230477A CA2230477A1 CA 2230477 A1 CA2230477 A1 CA 2230477A1 CA 002230477 A CA002230477 A CA 002230477A CA 2230477 A CA2230477 A CA 2230477A CA 2230477 A1 CA2230477 A1 CA 2230477A1
Authority
CA
Canada
Prior art keywords
levels
compound
apo
diazepine
triazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002230477A
Other languages
English (en)
French (fr)
Inventor
Herman Kempen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2230477A1 publication Critical patent/CA2230477A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002230477A 1995-09-09 1996-08-30 Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels Abandoned CA2230477A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95114163.9 1995-09-09
EP95114163 1995-09-09

Publications (1)

Publication Number Publication Date
CA2230477A1 true CA2230477A1 (en) 1997-03-13

Family

ID=8219597

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002230477A Abandoned CA2230477A1 (en) 1995-09-09 1996-08-30 Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels

Country Status (14)

Country Link
US (1) US5854238A (https=)
EP (1) EP0853480B1 (https=)
JP (1) JPH11512107A (https=)
KR (1) KR19990044460A (https=)
CN (1) CN1101680C (https=)
AT (1) ATE230600T1 (https=)
AU (1) AU725249B2 (https=)
BR (1) BR9610390A (https=)
CA (1) CA2230477A1 (https=)
DE (1) DE69625696T2 (https=)
DK (1) DK0853480T3 (https=)
ES (1) ES2188783T3 (https=)
TR (1) TR199800406T1 (https=)
WO (1) WO1997009048A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6253569B1 (en) * 1999-05-07 2001-07-03 James J. Hall Portable storage unit for game animals
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US20040235877A1 (en) 2001-09-14 2004-11-25 Natsuki Ishizuka Novel use of tricyclic compound
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
WO2006063132A2 (en) 2004-12-06 2006-06-15 The Regents Of The University Of California Methods for improving the structure and function of arterioles
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8569288B2 (en) 2008-10-30 2013-10-29 Circomed Llc Thienotriazolodiazepine derivatives active on apo A
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
WO2011143651A1 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
AU2014292888B2 (en) 2013-07-25 2018-03-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
CA2929652A1 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
SG11201607108XA (en) 2014-02-28 2016-09-29 Tensha Therapeutics Inc Treatment of conditions associated with hyperinsulinaemia
MX383117B (es) 2014-07-31 2025-03-13 Anji Pharmaceuticals Inc Péptidos miméticos de la apoe y mayor potencia para depurar el colesterol en plasma.
KR20170032474A (ko) 2014-08-08 2017-03-22 다나-파버 캔서 인스티튜트 인크. 디히드로프테리디논 유도체 및 그의 용도
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
BR112017008714A2 (pt) 2014-10-27 2017-12-19 Tensha Therapeutics Inc inibidores de bromodomínio
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
HK1256417A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
MX2020013608A (es) 2018-06-13 2021-03-09 Worg Pharmaceuticals Hangzhou Co Ltd Preparacion de derivados de triazepina condensados y su uso como inhibidores de bet.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12303A (en) * 1973-02-08 1979-01-16 Hoffmann La Roche Thienotriazolodiazepine derivatives
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
JPS50100096A (https=) * 1974-01-08 1975-08-08

Also Published As

Publication number Publication date
DK0853480T3 (da) 2003-05-05
EP0853480A1 (en) 1998-07-22
DE69625696T2 (de) 2003-10-16
AU6930396A (en) 1997-03-27
KR19990044460A (ko) 1999-06-25
EP0853480B1 (en) 2003-01-08
US5854238A (en) 1998-12-29
TR199800406T1 (en) 1998-05-21
CN1195989A (zh) 1998-10-14
CN1101680C (zh) 2003-02-19
AU725249B2 (en) 2000-10-12
MX9801753A (es) 1998-08-30
BR9610390A (pt) 1999-07-06
ATE230600T1 (de) 2003-01-15
JPH11512107A (ja) 1999-10-19
ES2188783T3 (es) 2003-07-01
WO1997009048A1 (en) 1997-03-13
DE69625696D1 (de) 2003-02-13

Similar Documents

Publication Publication Date Title
AU725249B2 (en) Use of a thienotriazolodiazepine to increase apolipoprotein A-I levels
CA1335813C (en) Administration of monoamine acridines in cholinergic neuronal deficit states
AU678559B2 (en) A method of increasing creatine supply depot
US6136859A (en) Pharmaceutical formulation for treating liver disorders
US5240961A (en) Method of treating reduced insulin-like growth factor and bone loss associated with aging
EP0825861B1 (en) High-dose chromic tripicolinate for the treatment of type ii diabetes
Klimov et al. “Essential” phospholipids versus nicotinic acid in the treatment of patients with type IIb hyperlipoproteinemia and ischemic heart disease
AU2020232295B2 (en) Medium chain triglyceride formulations with improved bioavailiblity and methods related thereto
US20020132855A1 (en) Use of acetaminophen to prevent and treat arteriosclerosis
WO1998001119A2 (en) Pharmaceutical compositions comprising simvastatin
WO2000043017A1 (en) Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human
JPH0232015A (ja) 薬剤の製造のためのモノ置換セレン有機化合物の使用、ならびにそれから製造される薬剤およびその薬剤の製造方法
US20020091103A1 (en) Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
WO1992006688A1 (en) New medical use for a certain indole derivative and pharmaceutical composition containing it
KR100794891B1 (ko) 씨디피-콜린 또는 그의 약학적으로 수용 가능한 염을 포함하는 알코올 금단 증후군의 치료용 약제 및 치료 방법
RU2095059C1 (ru) Способ профилактики и лечения атеросклероза
US5627152A (en) Method for increasing bodyweight
MXPA98001753A (en) Use of a thenotriazolodiazepine to increase apolipoprotein levels
KR20090115939A (ko) ２형 당뇨의 치료에 유용한 조성물
WO2003009840A1 (en) Composition comprising at least one lipase inhibitor and carnitine
JP3064360B2 (ja) 痴呆治療剤
US20250161270A1 (en) Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor
JPH0449235A (ja) 痴呆治療剤
MXPA01003569A (es) Combinacion de carnitinas y resveratrol para prevenir o tratar enfermedades cerebrales y del envejecimiento

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued